Aurinia Pharmaceuticals Inc. (AUPH) Sees Large Volume Increase
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) saw unusually-high trading volume on Tuesday . Approximately 14,975,110 shares traded hands during mid-day trading, an increase of 893% from the previous session’s volume of 1,507,369 shares.The stock last traded at $2.43 and had previously closed at $1.81.
AUPH has been the topic of a number of analyst reports. FBR & Co reiterated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research note on Monday. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Canaccord Genuity reissued a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, May 12th. HC Wainwright initiated coverage on Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They issued a “buy” rating and a $7.00 target price for the company. Finally, Leerink Swann reissued an “outperform” rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $7.15.
The firm’s market capitalization is $81.51 million. The firm has a 50-day moving average price of $3.20 and a 200 day moving average price of $2.79.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.